GE Healthcare Signs Distribution Agreement for DiscoveRx HitHunter cAMP Assays
News May 25, 2006
GE Healthcare and DiscoveRx have entered into an exclusive distribution agreement for all HitHunter™ cAMP Enzyme Fragment Complementation (EFC)-based assays, designed for high throughput, non-radioactive screening of compounds in drug discovery.
"We are very pleased to announce the expansion of our agreement with DiscoveRx, which grants GE Healthcare exclusive global distribution rights to HitHunter cAMP assays and provides our customers with more options for cutting edge, high throughput screening technology," says Ger Brophy, general manager of Discovery Sciences, at GE Healthcare.
"We are already known for our SPA screening products; adding the DiscoveRx portfolio allows us to offer a more comprehensive suite of screening technologies to our customers, combined with the high quality and service they have come to expect."
The agreement not only grants GE Healthcare global exclusivity for DiscoveRx’s cAMP assays, it also expands distribution of the company’s portfolio of kinase assays, with exclusive distribution in the Asia Pacific region.
HitHunter cAMP assays are homogeneous, non-radioactive, cell-based assays used to screen for G-protein coupled receptor (GPCR) activation in a microplate-based format.
"DiscoveRx’s HitHunter GPCR and kinase products are well accepted by drug discovery customers," says Pyare Khanna, Ph.D., CEO of DiscoveRx Corp.
"We are tremendously excited about this important step forward, which broadens the global access of our HitHunter products through a premier supplier of life science research tools."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019